Johnson & Johnson announced  it is discontinuing the Phase II field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the prevention of dengue virus in adults aged 18-65 years

强生公司宣布停止第二阶段实地研究（NCT05201794），该研究评估了研究性抗病毒候选药物Mosnodevir对18-65岁成年人预防登革热病毒的疗效

The decision to discontinue this study is part of a strategic reprioritization of the Company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.

停止这项研究的决定是该公司传染病研究与开发（R＆D）投资组合战略重新优先的一部分。未发现任何安全问题。

Efficacy data from the Phase II field study will be available once the final data analyses, which are now underway, are complete. Study investigators have been notified of the discontinuation. All participants have completed the study per protocol and will be notified of the results once they are ready..

一旦目前正在进行的最终数据分析完成，即可获得II期现场研究的疗效数据。研究调查人员已被告知停药。所有参与者均已按照方案完成研究，并将在准备好后通知结果。。

Mosnodenvir (formerly JNJ 1802) was shown to be safe and well tolerated in previous Phase 1 and Phase IIa clinical studies. Results from the Phase IIa human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.

Mosnodevir（以前的JNJ 1802）在先前的1期和IIa期临床研究中被证明是安全且耐受性良好的。IIa期人类挑战研究的结果发现，与安慰剂相比，该化合物诱导了人类对登革热（DENV-3）的抗病毒活性。

Condition: Dengue

病情：登革热

Type: drug

类型：药物